Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07251153
PHASE1

Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions

Sponsor: Enyo Pharma

View on ClinicalTrials.gov

Summary

The purpose of this study is to define and compare the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EYP651 at two dose levels and compare it with Vonafexor Acid PK and PD profile, the Part A. In addition, Part B of the trial will assess the Drug-Drug Interactions (DDI) potential with the high dose of EYP651.

Official title: A Phase 1, Two Parts, Open-label, Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt (EYP651) in Healthy Volunteers and Evaluation of Potential Drug-Drug Interactions

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-10-28

Completion Date

2026-10-28

Last Updated

2026-02-27

Healthy Volunteers

Yes

Interventions

DRUG

EYP651/Vonafexor low dose

Repeated daily dosing with EYP651 or Vonafexor Acid for 5 days, cross-over at low dose according to period 1

DRUG

EYP651/Vonafexor high dose

Repeated daily dosing with EYP651 or Vonafexor Acid for 5 days, cross-over at high dose according to period 1

DRUG

EYP651/CYP3A4 inhibitor

Repeated daily dosing with EYP651 alone in period 1, and combined administration repeated daily dosing of EYP651 with index drug 1 (CYP3A4 inhibitor) in period 3. Parallel group 1

DRUG

EYP651/Transporter substrate

Repeated daily dosing with EYP651 alone in period 1, and combined administration repeated daily dosing of EYP651 with index drug 2 (Transporter substrate) in period 3. Parallel group 2

DRUG

EYP651/CYP2C8 and CYP2C9 substrate

Repeated daily dosing with EYP651 alone in period 1, Repeated daily dosing with the index drug 3 alone in period 2 and combined administration repeated daily dosing of EYP651 with index drug 3 (CYP2C8 and CYP2C9 substrate) in period 3. Parallel group 3

Locations (1)

Eurofins Optimed

Gières, France